Mortality rates of patients treated with Drotrecogin alfa for severe Sepsis based on PROWESS eligibility

M. Goodwin, R. H. Drew, D. B. May, A. Scates, E. Dodds-Ashley

Research output: Contribution to conferencePoster

Original languageAmerican English
StatePublished - Jan 1 2007

Disciplines

  • Pharmacy and Pharmaceutical Sciences

Cite this